JKB-122 is an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis and nonalcoholic fatty liver disease. The drug was transferred to Biostax in 2022.
References
Wikipedia
JKB-122
Tags
- Drugs with undisclosed chemical structures
- Experimental drugs
- Pharmacology stubs
- Receptor antagonists
- Small-molecule drugs